Well, it's buried in the 10-K's. The British partner was sold, the Aussie buyer changed their co. name to Oncosil. What makes oncosil of more imminent interest is that oncosil is following the medical device route... PMA, so much faster approval if the results are good enough.
The company's single biggest patent estate is in biosilicon. Like you say they very seldom say a word, and they are very quiet about it, but their existing partner Oncosil filed an IDE for psvidia's biosilicon this Jan in pancreatic cancer... should be hearing back after the summer? Only 8% royalty but this could be another billion dollar opportunity... like Sirtex. Small company and limited cash... worse than Alimera... so although patients do not survive long a trial will be slow for other reasons. And then there is Pfizer... should they ever bite.
Almost back to the SP we were at 20 years ago, forgetting a y2k spike. Blueline rescued us, paying some 60c for some shares, some 7yrs ago now. That is a LONG time for a special situations fund, but then blueline doesn't do much! They have been distributing shares back to fund partners. If they were selling maybe it's a case of liquidity just improving. Topline growth is still yet to happen in a major way,what has changed here is the multiple...
From 145ish at bid to 190 share price. If most of that is based on this acquisition, then Celator went for half price! Time for a counter offer..arb spread still says yes.
There are a lot of reasons to invest here but OA is unlikely to be one of them. You need something like HA in the joint to act as a lubricant as well. So that's 2 procedures not one. Then again, why use a surgical bone insert when an injected particle gel will do: like Flexion. Best data so far has come from Cingal, steroid+HA, but FDA wants to treat Cingal as a drug not a 510k app. Longer acting, maybe, is nice, but does not make a business case for the doc to use it.
I'd say a non-negative, and minor at that...
What the fda does with cingal is the long-term issue, discounted to today i'd say approval = +20 if not in price already
Failed to show better than saline. Was a new approach, but saline is pretty good at wk 12 as flexion found out! Now they say they will pool data to try and get an indication - fda will say no of course.
We now have 5 failed, partially failed, or held up trials in knee OA in 12m.
Stock market values both co.s every day - by definition. They are dragging each other down it seems (ok, correlation is there, not causation!), I think they could pull each other up. I buy these for the risk/reward, as do other investors... the management get a rent whatever happens... even when they go to zero.
Maybe people are missing the: "investigator-sponsored study" bit! ie Marinus did not "do it".
Ganaxolone should work .. it does, just not well enough in eplilepsy , maybe not here either.
Agreed, that psdv has the better reward/risk profile... but i'd rather see further dilution at 12+ than 4 as now. Would one take it "for free"... of course, so issue is only the price... ie ratio. A fully integrated pharma co. always gets a higher multiple anyway.
to be emphasized that the really rare thing here is not the 40ish% growth, but the fact that the company was able to escape a toxic financing trap after a back-door listing... kind of a white swan.
Nov13 14 this became investible. In some 18 months, we have seen a 2.5x rise in the share price despite the dilution. Normally at 6x sales a medtech stock would be fully valued. But 40% growth is hard to get anywhere. So rare bigger companies gleefully pay for it ...
Here we all likely think this co. is the more valuable one in the long term, so no sense in, say, merging with ALIM. But as the relative value of ALIM drops, the math starts to change. a 95ish % gross margin on 2+ products making money already in 2017, even if one is only in Europe, would be worth a lot more than the 130 m combined EV at the moment. Of course, makes sense only if psdv's cash suffices for the combination. Alone, Alim has a ton of dilution risk priced in, but that goes away with 30 m of cash... IF they had that cash, I'd say ALIM share price would be back to 5 or even 10 after modest progress in Q2... meaning combination at 1:1 ratio would be worth 3-4 x what it is today.... ie within weeks not years!
No idea. Reason for latest drop is obvious. however, methinks Asian factories toolup late summer for the end of year demand, so a normal q2 might be followed by a good q3.
Well, i was thinking a new ATH was on the cards 2 months ago. Nothing changed in the meantime. Well, a bit more progress on Cingal ex-USA. Competition not done well. Maybe folks think FDA will reply to Anika by summer?
Well, comentators say that it was a closed deal, so +70% offered to keep out all but serious bidders. BUT if someone else is interested it is not just 10% more, it is more like 100% more....so 60?
Chatter says Jazz tried ot bid for aspx ... but could only raise 3b... so lost to teva. If this is known, could be the players force jazz to max out. Logic is that that keeps Jazz away from other deals. If they get us on the cheap, the reverse happens.. firepower just gets better.